Bokf Na Reduces Position in Zoetis Inc. $ZTS

Key Points

• Bokf Na cut its stake in Zoetis by 31.9% in Q4, selling 15,784 shares and ending the period with 33,705 shares valued at about $4.24 million.
• Several large institutions ramped up positions — notably Vanguard (+12.9% to 47.78 million shares, ~$6.01 billion) while Nordea and Montrusco made double- and triple-digit increases — and institutional investors now own about 92.8% of the stock.
• Zoetis beat Q results (EPS $1.48 vs. $1.40 est., revenue $2.39B, +3% YoY), set FY2026 guidance of $7.00–$7.10 EPS, and trades near $111.55 versus a consensus analyst rating of "Hold" and an average price target of $151.75.

Bokf Na lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 31.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,705 shares of the company's stock after selling 15,784 shares during the period. Bokf Na's holdings in Zoetis were worth $4,241,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ZTS. Vanguard Group Inc. boosted its position in shares of Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock valued at $6,011,802,000 after buying an additional 5,474,210 shares during the period. Diamond Hill Capital Management Inc. bought a new stake in shares of Zoetis during the third quarter valued at approximately $394,010,000. Nordea Investment Management AB raised its stake in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Montrusco Bolton Investments Inc. boosted its holdings in shares of Zoetis by 256.7% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company's stock valued at $266,888,000 after purchasing an additional 1,560,314 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its stake in Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company's stock worth $394,746,000 after purchasing an additional 1,227,085 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Down 0.9%

Zoetis stock opened at $111.55 on Thursday. The business has a fifty day moving average of $119.33 and a two-hundred day moving average of $124.10. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market cap of $46.92 billion, a P/E ratio of 18.53, a P/E/G ratio of 1.73 and a beta of 0.87. Zoetis Inc. has a twelve month low of $110.94 and a twelve month high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the prior year, the business posted $1.40 EPS. The business's revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts forecast that Zoetis Inc. will post 7.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ZTS shares. Citigroup started coverage on Zoetis in a research note on Wednesday, April 15th. They issued a "buy" rating and a $145.00 price objective on the stock. UBS Group dropped their price objective on Zoetis from $136.00 to $130.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 28th. Leerink Partners reissued a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. Weiss Ratings cut Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 27th. Finally, Piper Sandler reissued a "neutral" rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $151.75.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.